Biosergen AB
Develops drugs to treat severe and resistant invasive fungal infections.
BIOSGN | ST
Overview
Corporate Details
- ISIN(s):
- SE0016013460 (+2 more)
- LEI:
- 549300YD2OGUE7BMP925
- Country:
- Sweden
- Address:
- Fogdevreten 2, 171 65 Solna
- Website:
- https://biosergen.net/
- Sector:
- Manufacturing
Description
Biosergen AB is a clinical-stage biotechnology company developing innovative drugs to treat severe and resistant invasive fungal infections. The company's lead candidate, BSG005, is a genetically improved, broad-spectrum polyene macrolide. It is designed to be fungicidal, killing the fungus rather than only inhibiting its growth, and aims to provide a superior safety and potency profile compared to existing treatments. The primary target patient population is immunocompromised individuals, such as those with cancer, AIDS, or who have undergone organ transplants. BSG005 has completed a Phase 1 safety study and is advancing in clinical development. The candidate has received Orphan Drug Designation from the U.S. FDA and is protected by patents until 2043.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Biosergen AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biosergen AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biosergen AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
